Lancet ID Commentary to the G20 on behalf of the DRIVE-AB Steering Committee

I am pleased to say that a commentary to the G20 on behalf of the DRIVE-AB Steering Committee has now gone live in the Online First section of Lancet Infectious Diseases. The article is not Open Access so you’ll have to download it for yourself (link below).

The commentary summarises some of DRIVE-AB’s preliminary findings that are pertinent to the G20 discussions as this list of recommendations:

  • Immediately fill the gap of US$250 million per year in push funding; existing mechanisms require additional financing and are well suited for an immediate in-flow of extra financing
  • Implement market entry reward pilots to learn about the operationalisation of such models
  • Request that regional and global banking institutions (such as the European Investment Bank and the World Bank) examine potential novel financial instruments to support further antibacterial R&D funding
  • Establish a mechanism for multinational coordination and collaboration
  • Develop health technology assessment processes and rules of reimbursement to consider the resistance situation and capture antibiotic societal value

DRIVE-AB’s complete findings will be published and presented at the DRIVE-AB conference in Brussels on Sept 5–6, 2017. 

Best wishes and stayed tuned for further developments! –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust | Follow me on Twitter: @JohnRex_NewAbx

Upcoming events of note outside of the mainstream large meetings:

  • 10-11 July: FDA workshop on bacteriophage therapies
  • 19 July: FDA workshop on combination therapy for TB
  • 5-9 Sep: ASM-ESCMID conference on antibiotic R&D, including the CARB-X + GARDP Antibiotic Bootcamp
  • 13 Sep 2017 (DC): FDA-CDRH workshop on diagnostic devices for detecting antimicrobial susceptibility & resistance

Link to online article: http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30404-8/abstract

Share

How the sausage is made: A day of advocacy for PASTEUR

Dear All, Along with more than 50 others, I spent Tuesday 12 Sep 2023 on Capitol Hill visiting offices of members of Congress (Senate and House) seeking support for the PASTEUR Act. If you’re a regular reader, you’ll know that we now have substantial bipartisan support for PASTEUR: it was re-introduced as The Pioneering Antimicrobial

Canada says, “Let’s pull together!” in a major new report

Dear All (and with thanks to Kevin for co-authoring): Yesterday saw the release of a major new report on Pull incentives from Canada! The report’s cover art eloquently summarizes its key message: Well said … and proves that a picture really is worth 1,000 words! Here are the links you’ll need: The report’s webpage at the

€100m HERA Invest fund; Sign to support PASTEUR; Superb AMR movie!

Dear All,  Expanding the available Push funding, the EU’s HERA (Health Emergency Preparedness and Response Authority) has created HERA Invest by allocating €100m in support early and late phases of clinical trials. HERA Invest is open on a rolling application basis to EU-based SMEs developing medical countermeasures that address one of the following cross-border health threats: (i)

Scroll to Top